Skip to main content
SpringerLink
Log in

Increased expression of BIRC5 in non-small cell lung cancer and esophageal squamous cell carcinoma does not correlate with the expression of its inhibitors SMAC/DIABLO and PML

  • Cell Molecular Biology
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

Survivin (BIRC5) belongs to the family of inhibitors of apoptosis proteins (IAPs). BIRC5 is expressed in embryonic tissues and in most malignant tumors but not in fully differentiated adult tissues. BIRC5, acting as an apoptosis inhibitor, presumably plays an important part in carcinogenesis, thus providing an attractive target for antitumor therapy. The mechanisms regulating the survivin level are insufficiently understood, but a significant role is ascribed to natural survivin inhibitors, SMAC and PML. The transcription levels of BIRC5, SMAC, and PML and the levels of their protein products were assessed by RT-PCR and immunoblotting in normal and tumor human tissues in non-small cell lung cancer and esophageal squamous cell carcinoma. BIRC5 transcription was observed only in tumor tissues, whereas SMAC and PML were expressed in tumor and normal tissues at similar levels. The protein levels corresponded to the mRNA levels. Thus, increased levels of survivin in tumor tissues are not a consequence of downregulation of its inhibitors SMAC and PML, whose levels do not differ between tumor and normal cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Philchenkov A., Zavelevich M., Kroczak T.J., Los M. 2004. Caspases and cancer: Mechanisms of inactivation and new treatment modalities. Exp. Oncol. 26, 82–97.

    PubMed  CAS  Google Scholar 

  2. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., Albelda S.M. 2005. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in nonsmall cell lung cancer: A review. Clin. Cancer Res. 11, 3974–3986.

    Article  PubMed  CAS  Google Scholar 

  3. Ambrosini G., Adida C., Altieri D.C. 1997. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917–921.

    Article  PubMed  CAS  Google Scholar 

  4. Colnaghi R., Connell C.M., Barrett R.M., Wheatley S.P. 2006. Separating the anti-apoptotic and mitotic roles of survivin. J. Biol. Chem. 281, 33450–33456.

    Article  PubMed  CAS  Google Scholar 

  5. Wheatley S.P., McNeish I.A. 2005. Survivin: a protein with dual roles in mitosis and apoptosis. Int. Rev. Cytol. 247, 35–88.

    Article  PubMed  CAS  Google Scholar 

  6. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. 1998. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43–49.

    PubMed  CAS  Google Scholar 

  7. Fukuda S., Pelus L.M. 2006. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 5, 1087–1098.

    Article  PubMed  CAS  Google Scholar 

  8. Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D. 1999. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59, 6097–6102.

    PubMed  CAS  Google Scholar 

  9. Ling X., Yang J., Tan D., Ramnath N., Younis T., Bundy B.N., Slocum H.K., Yang L., Zhou M., Li F. 2005. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer. 49, 353–361.

    Article  PubMed  Google Scholar 

  10. Sampath J., Pelus L.M. 2007. Alternative splice variants of survivin as potential targets in cancer. Curr. Drug Discov. Technol. 4, 174–191.

    Article  PubMed  CAS  Google Scholar 

  11. Duffy M.J., O’Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. 2007. Survivin: A promising tumor biomarker. Cancer Lett. 249, 49–60.

    Article  PubMed  CAS  Google Scholar 

  12. Fan J., Wang L., Jiang G.N., He W.X., Ding J.A. 2008. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer, doi:10.1016/j.lungcan.2007.11.011.

  13. Altieri D.C. 2008. Survivin, cancer networks, and pathway-directed drug discovery. Nat. Rev. Cancer. 8, 61–70.

    Article  PubMed  CAS  Google Scholar 

  14. Li F. 2005. Role of survivin and its splice variants in tumorigenesis. Br. J. Cancer. 92, 212–216.

    PubMed  CAS  Google Scholar 

  15. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. 2000. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 102, 43–53.

    Article  PubMed  CAS  Google Scholar 

  16. Shiozaki E.N., Shi Y. 2004. Caspases, IAPs and Smac/DIABLO: Mechanisms from structural biology. Trends Biochem. Sci. 29, 486–494.

    Article  PubMed  CAS  Google Scholar 

  17. Xu Z.X., Zhao R.X., Ding T., Tran T.T., Zhang W., Pandolfi P.P., Chang K.S. 2004. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J. Biol. Chem. 279, 1838–1844.

    Article  PubMed  CAS  Google Scholar 

  18. Rajalingam K., Oswald M., Gottschalk K., Rudel T. 2007. Smac/DIABLO is required for effector caspase activation during apoptosis in human cells. Apoptosis. 12, 1503–1510.

    Article  PubMed  CAS  Google Scholar 

  19. Sekimura A., Konishi A., Mizuno K., Kobayashi Y., Sasaki H., Yano M., Fukai I., Fujii Y. 2004. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol. Rep. 11, 797–802.

    PubMed  CAS  Google Scholar 

  20. Krepela E., Prochazka J., Fiala P., Zatloukal P., Selinger P. 2006. Expression of apoptosome pathway-related transcripts in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 132, 57–68.

    Article  PubMed  CAS  Google Scholar 

  21. Ceballos-Cancino G., Espinosa M., Maldonado V., Melendez-Zajgla J. 2007. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene. 26, 7569–7575.

    Article  PubMed  CAS  Google Scholar 

  22. Vogler M., Giagkousiklidis S., Genze F., Gschwend J.E., Debatin K.M., Fulda S. 2005. Inhibition of clonogenic tumor growth: A novel function of Smac contributing to its antitumor activity. Oncogene. 24, 7190–7202.

    Article  PubMed  CAS  Google Scholar 

  23. Salomoni P., Pandolfi P.P. 2002. The role of PML in tumor suppression. Cell. 108, 165–170.

    Article  PubMed  CAS  Google Scholar 

  24. Bernardi R., Pandolfi P.P. 2003. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene. 22, 9048–9057.

    Article  PubMed  CAS  Google Scholar 

  25. Li L., He D., He H., Wang X., Zhang L., Luo Y., Nan X. 2006. Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway. Cancer Lett. 236, 259–268.

    Article  PubMed  CAS  Google Scholar 

  26. Chan J.Y., Li L., Fan Y.H., Mu Z.M., Zhang W.W., Chang K.S. 1997. Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML. Biochem. Biophys. Res. Commun. 240, 640–646.

    Article  PubMed  CAS  Google Scholar 

  27. Salomoni P., Bellodi C. 2007. New insights into the cytoplasmic function of PML. Histol. Histopathol. 22, 937–946.

    PubMed  CAS  Google Scholar 

  28. Fagioli M., Alcalay M., Pandolfi P.P., Venturini L., Mencarelli A., Simeone A., Acampora D., Grignani F., Pelicci P.G. 1992. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene. 7, 1083–1091.

    PubMed  CAS  Google Scholar 

  29. Jensen K., Shiels C., Freemont P.S. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20, 7223–7233.

    Article  PubMed  CAS  Google Scholar 

  30. Condemine W., Takahashi Y., Zhu J., Puvion-Dutilleul F., Guegan S., Janin A., de The H. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 66, 6192–6198.

    Article  PubMed  CAS  Google Scholar 

  31. Condemine W., Takahashi Y., Le Bras M., de The H. 2007. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J. Cell Sci. 120, 3219–3227.

    Article  PubMed  CAS  Google Scholar 

  32. Slizhikova D.K., Zinov’eva M.V., Kuz’min D.V., Snezhkov E.V., Shakhparonov M.I., Dmitrirev R.I., Antipova N.V., Zavalova L.L., Sverdlov E.D. 2007. Decrease in expression of human J-chain in lung squamous cell cancer and adenocarcinoma. Mol. Biol. 41, 659–665.

    Article  CAS  Google Scholar 

  33. Harlow E., Lane D. 1988. Antibodies. A laboratory manual. Cold Spring Harbor, NY: CSG Press.

    Google Scholar 

  34. Ikeguchi M., Kaibara N. 2002. survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br. J. Cancer. 87, 883–887.

    Article  PubMed  CAS  Google Scholar 

  35. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., Mitsui A., Nishiwaki T., Moriyama S., Kudo J., Fujii Y. 2001. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int. J. Cancer. 95, 92–95.

    Article  PubMed  CAS  Google Scholar 

  36. Gambacorta M., Flenghi L., Fagioli M., Pileri S., Leoncini L., Bigerna B., Pacini R., Tanci L.N., Pasqualucci L., Ascani S., Mencarelli A., Liso A., Pelicci P.G., Falini B. 1996. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am. J. Pathol. 149, 2023–2035.

    PubMed  CAS  Google Scholar 

  37. Zhang P., Chin W., Chow L.T., Chan A.S., Yim A.P., Leung S.F., Mok T.S., Chang K.S., Johnson P.J., Chan J.Y. 2000. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int. J. Cancer. 85, 599–605.

    Article  PubMed  CAS  Google Scholar 

  38. Vousden K.H., Lu X. 2002. Live or let die: The cell’s response to p53. Nature Rev. Cancer. 2, 594–604.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia

    N. A. Vayshlya, M. V. Zinovyeva, A. V. Sass, E. P. Kopantzev, T. V. Vinogradova & E. D. Sverdlov

Authors
  1. N. A. Vayshlya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. V. Zinovyeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. Sass
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. P. Kopantzev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. V. Vinogradova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. D. Sverdlov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. V. Zinovyeva.

Additional information

Original Russian Text © N.A. Vayshlya, M.V. Zinovyeva, A.V. Sass, E.P. Kopantzev, T.V. Vinogradova, E.D. Sverdlov, 2008, published in Molekulyarnaya Biologiya, 2008, Vol. 42, No. 4, pp. 652–661.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vayshlya, N.A., Zinovyeva, M.V., Sass, A.V. et al. Increased expression of BIRC5 in non-small cell lung cancer and esophageal squamous cell carcinoma does not correlate with the expression of its inhibitors SMAC/DIABLO and PML . Mol Biol 42, 579–587 (2008). https://doi.org/10.1134/S0026893308040146

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893308040146

Key words

Search

Navigation